Hideyuki Akaza, Shiro Hinotsu, Michiyuki Usami, Yoichi Arai, Hiroshi Kanetake, Seiji Naito and Yoshihiko Hirao Combined androgen blockade with bicalutamide for advanced prostate cancer Cancer 115
Version of Record online: 17 JUN 2009 | DOI: 10.1002/cncr.24395
The long-term follow-up of the first double-blind, randomized study to directly compare combined androgen blockade (CAB) with bicalutamide 80 mg versus lutenizing hormone-releasing hormone agonist (LHRH-A) monotherapy demonstrated a significant overall survival advantage in favor of CAB. More patients who received CAB achieved a prostate-specific antigen (PSA) nadir of ≤1 ng/mL than patients who received LHRH-A monotherapy, and the patients who attained a PSA nadir of ≤1 ng/mL survived significantly longer than patients with PSA levels that remained above 1 ng/mL.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field